Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs) using its proprietary ATAC technology, announced that shareholders approved all management proposals by a large majority at the company's ordinary virtual Annual General Meeting held today. The meeting, which saw attendance of 80.55% of the current capital stock, approved resolutions with votes ranging from 98.67% to 98.72%.
Key decisions included the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Additionally, shareholders elected Mr. Jack Yefei Ling as a new member of the Supervisory Board and approved an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members. This restructuring reflects the company's ongoing strategic focus on advancing its pipeline of ATAC candidates.
Heidelberg Pharma is pioneering the use of Amanitin, a toxin derived from the death cap mushroom, in cancer therapy. Its lead candidate, HDP-101 (INN: pamlectabart tismanitin), targets BCMA for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the FDA. The company's second candidate, HDP-102, is in clinical development for Non-Hodgkin Lymphoma, while HDP-103 and HDP-104 have completed preclinical development for metastatic castration-resistant prostate cancer and gastrointestinal tumors, respectively. These programs are available for partnering, highlighting the company's collaborative approach to bringing novel therapies to market.
For more details on the meeting and voting results, visit the company's Annual General Meeting page. Heidelberg Pharma is listed on the Frankfurt Stock Exchange under the symbol HPHA, with more information available at www.heidelberg-pharma.com.
